Emideltide (DSIP)

What it is

Emideltide is the regulatory name used in FDA's review of the peptide widely known as DSIP. It was originally investigated for effects on sleep and later appeared in small studies involving insomnia, narcolepsy, and withdrawal.

What humans actually show

• Early controlled study: A 1981 double-blind crossover study administered intravenous synthetic DSIP to six healthy volunteers. It reported changes in short-term sleep measures and subsequent-night sleep. Six people are far too few to establish effectiveness or characterize safety.
• Broader old literature: FDA reviewed several small intravenous studies. Some reported improved sleep outcomes, while other similarly designed double-blind placebo-controlled studies did not reach the same conclusions.
• FDA's assessment: FDA describes the chronic-insomnia evidence as inconclusive and at best preliminary. It cites small samples, inconsistent results, weak or poorly selected control groups, different baseline characteristics, varied regimens, and unknown long-term benefit.
• Route mismatch: FDA identified intravenous human studies but no clinical data for the nominated subcutaneous route.

The honest label is “human research exists, but it does not settle the claim.”

FDA and U.S. status

FDA evaluated emideltide free base and emideltide acetate for chronic insomnia, narcolepsy, and opioid withdrawal. Staff concluded the criteria weigh against including either substance on the 503A Bulks List.

FDA found that published intravenous studies included 209 subjects across short exposures, but this does not establish safety for subcutaneous products or long-term use. On July 24, 2026, PCAC voted 6 yes, 7 no, 1 abstain on the free base and 6 yes, 7 no, 1 abstain on the acetate, recommending against inclusion for both forms. The advisory result is not a product approval or a final FDA determination.

Risks and warning limits

FDA says available small intravenous studies generally reported no significant adverse effects in chronic-insomnia subjects, while some transient effects appeared in withdrawal studies. It concludes there are no safety data for the proposed subcutaneous route. Limited short-term tolerability is not the same as a characterized long-term safety profile.

PepCurrent does not provide dosing, sourcing, or product-selection advice.

What would change this answer

• FDA's written meeting record and final determination after the advisory recommendation
• Modern, preregistered randomized trials with clinically meaningful sleep outcomes
• Route-specific safety, pharmacokinetic, and long-term data

Sources and records

• FDA staff briefing — emideltide-related bulk drug substances (2026)
• Schneider-Helmert et al., 1981 — six-person double-blind crossover study
• FDA meeting page — July 23–24, 2026 PCAC
• FDA voting questions — exact free-base and acetate questions (PDF)
• FDA-linked Day 2 archived broadcast — emideltide votes

Educational journalism only; not medical or legal advice. We do not link vendors or publish protocols.